<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02086682</url>
  </required_header>
  <id_info>
    <org_study_id>13-003161</org_study_id>
    <nct_id>NCT02086682</nct_id>
  </id_info>
  <brief_title>A Prospective Study of Airless Tubing in an Inpatient Acute Hemodialysis Unit in Hospitalized Patients</brief_title>
  <official_title>A Prospective Study of Airless Tubing in an Inpatient Acute Hemodialysis Unit in Hospitalized Patients in a Large Medical Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marie Hogan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NxStage Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The introduction of unfractionated heparin (UFH), which prevents clotting of the
      extracorporal circuit, was one of the key advances that led to the rapid development and
      expansion of hemodialysis services. However, anticoagulation during hemodialysis of the
      patient at high risk for bleeding remains a frequently encountered problem in both inpatient
      and outpatient dialysis practice.

      Streamline bloodlines are designed to eliminate blood-air contact. This is thought to help
      reduce heparin use and decrease clotting rates. The goal of this study was to prospectively
      examine impact of the Streamline airless blood tubing set, in an inpatient setting, on
      dialysis circuit clotting rates, anticoagulation use, and dialysis efficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The introduction of unfractionated heparin (UFH), which prevents clotting of the
      extracorporeal circuit, was one of the key advances that led to the rapid development and
      expansion of hemodialysis use, and remains the mainstay in hemodialysis practice today.

      However, anticoagulation during hemodialysis of the patient at high risk for bleeding remains
      a frequently encountered problem in the nephrology practice. The need for anticoagulation to
      prevent clotting of the extracorporeal blood circuit and the need to prevent anticoagulation
      related bleeding complications in the patient has led to the development of numerous
      strategies; the safest from a bleeding standpoint being anticoagulant-free hemodialysis.

      Streamline® bloodlines (Medisystems® Corporation, Lawrence, MA) are designed to eliminate
      blood-air contact. A pressure pod measures arterial and venous pressures without any
      blood-air contact. The venous chamber is run without an air gap. It is also designed so that
      blood flows in a circular vortex manner. This airless system is thought to provide several
      benefits: improved dialysis efficiency and blood flow rates, reduced heparin use and clotting
      rates.

      The goal of this study was to prospectively examine the Streamline® airless tubing system in
      an inpatient setting and its association with clotting rates, and dialysis efficiency.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clotting of Extracorporeal Dialysis Circuit</measure>
    <time_frame>During the dialysis session, approximately 211 minutes</time_frame>
    <description>Each dialysis session was prospectively observed for Clotting of Extracorporeal Dialysis Circuit. Events were defined as interruption of hemodialysis session, loss of the hemodialysis circuit, or inability to return blood to the patient upon rinse back.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">338</enrollment>
  <condition>End Stage Renal Failure on Dialysis</condition>
  <condition>Complication of Dialysis</condition>
  <condition>Blood Coagulation Disorders</condition>
  <arm_group>
    <arm_group_label>General Care Cohort</arm_group_label>
    <description>The group included adult hospitalized patients requiring hemodialysis at the inpatient dialysis unit. This was an observational study, with no interventions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Critical Care Cohort</arm_group_label>
    <description>The group included adult hospitalized patients requiring hemodialysis at the intensive care unit. This was an observational study, with no interventions.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The group included adult hospitalized patients requiring hemodialysis at the inpatient
        dialysis unit or the ICU during the recruitment period.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult non-pregnant patients requiring inpatient hemodialysis at our center during
             the recruitment period until the target sample of dialysis sessions (n=1200) was
             reached.

        Exclusion Criteria:

          -  Pregnant females

          -  Children
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie C. Hogan, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Hospital, Saint Marys Campus</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Safadi S, Albright RC Jr, Dillon JJ, Williams AW, Alahdab F, Brown JK, Severson AL, Kremers WK, Ryan MA, Hogan MC. Prospective Study of Routine Heparin Avoidance Hemodialysis in a Tertiary Acute Care Inpatient Practice. Kidney Int Rep. 2017 Mar 16;2(4):695-704. doi: 10.1016/j.ekir.2017.03.003. eCollection 2017 Jul.</citation>
    <PMID>29142987</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 10, 2014</study_first_submitted>
  <study_first_submitted_qc>March 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <results_first_submitted>September 13, 2017</results_first_submitted>
  <results_first_submitted_qc>May 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 15, 2019</results_first_posted>
  <last_update_submitted>May 1, 2019</last_update_submitted>
  <last_update_submitted_qc>May 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Marie Hogan</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>dialysis</keyword>
  <keyword>renal dialysis</keyword>
  <keyword>clotting</keyword>
  <keyword>coagulation</keyword>
  <keyword>blood lines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>338 patients were enrolled at the Mayo Clinic in Rochester, Minnesota from January 2014 to May 2015.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>General Care Cohort</title>
          <description>The group included adult hospitalized patients requiring hemodialysis at the inpatient dialysis unit. This was an observational study, with no interventions.</description>
        </group>
        <group group_id="P2">
          <title>Critical Care Cohort</title>
          <description>The group included adult hospitalized patients requiring hemodialysis at the intensive care unit. This was an observational study, with no interventions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="182"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="182"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>General Care Cohort</title>
          <description>The group included adult hospitalized patients requiring hemodialysis at the inpatient dialysis unit. This was an observational study, with no interventions.</description>
        </group>
        <group group_id="B2">
          <title>Critical Care Cohort</title>
          <description>The group included adult hospitalized patients requiring hemodialysis at the intensive care unit. This was an observational study, with no interventions.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="156"/>
            <count group_id="B2" value="182"/>
            <count group_id="B3" value="338"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="16"/>
                    <measurement group_id="B2" value="62" spread="17"/>
                    <measurement group_id="B3" value="62.5" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="296"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clotting of Extracorporeal Dialysis Circuit</title>
        <description>Each dialysis session was prospectively observed for Clotting of Extracorporeal Dialysis Circuit. Events were defined as interruption of hemodialysis session, loss of the hemodialysis circuit, or inability to return blood to the patient upon rinse back.</description>
        <time_frame>During the dialysis session, approximately 211 minutes</time_frame>
        <population>Units in the study referred to a dialysis session. A patient could have received dialysis more than once. Hence the number of patients (338) is less than the number of dialysis sessions (1200).</population>
        <group_list>
          <group group_id="O1">
            <title>General Care Cohort</title>
            <description>The group included adult hospitalized patients requiring hemodialysis at the inpatient dialysis unit. This was an observational study, with no interventions.</description>
          </group>
          <group group_id="O2">
            <title>Critical Care Cohort</title>
            <description>The group included adult hospitalized patients requiring hemodialysis at the intensive care unit. This was an observational study, with no interventions.</description>
          </group>
        </group_list>
        <measure>
          <title>Clotting of Extracorporeal Dialysis Circuit</title>
          <description>Each dialysis session was prospectively observed for Clotting of Extracorporeal Dialysis Circuit. Events were defined as interruption of hemodialysis session, loss of the hemodialysis circuit, or inability to return blood to the patient upon rinse back.</description>
          <population>Units in the study referred to a dialysis session. A patient could have received dialysis more than once. Hence the number of patients (338) is less than the number of dialysis sessions (1200).</population>
          <units>Clotting events</units>
          <param>Number</param>
          <units_analyzed>Dialysis Sessions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Dialysis Sessions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="600"/>
                <count group_id="O2" value="600"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days after hospital admission</time_frame>
      <group_list>
        <group group_id="E1">
          <title>General Care Cohort</title>
          <description>The group included adult hospitalized patients requiring hemodialysis at the inpatient dialysis unit. This was an observational study, with no interventions.</description>
        </group>
        <group group_id="E2">
          <title>Critical Care Cohort</title>
          <description>The group included adult hospitalized patients requiring hemodialysis at the intensive care unit. This was an observational study, with no interventions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Marie Hogan</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266 -1963</phone>
      <email>Hogan.Marie@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

